is an enzyme blend specially designed to provide support for the
intestinal track, thus discouraging the colonization of Candida
albicans. Candida albicans is an opportunistic pathogen, which
can cause serious infections in those with compromised immune system.
Unlike animal cells, fungi are encompassed by a rather rigid cell
wall, which provides protection from environmental extremes. The cell
wall of Candida albicans is primary composed of branched glucose
polymers (Glucans), N-acetyl-glucosamine (Chitin), and polymers of
mannose (mannan) associated with proteins (mannoproteins).
is a complex consisting of three enzymes that together convert
cellulose (one of the basic components of cell walls) to glucose.
Cellulase contributes to the effective breakdown of some of the
specific fibrous cell walls present in grain, fruit and vegetables.
It is also thought that Candida’s cell wall may be vulnerable to
cellulose digestion. Theoretically, cellulose would disrupt the cell
and the yeast would subsequently die.
is an enzyme that attacks the protective cell walls of bacteria.
Bacteria build a though skin of carbohydrate chain, interlocked by
short peptide strands, which brace their delicate membrane against
the cell’s high osmotic pressure. Lysozyme breaks these
carbohydrate chains, destroying the structural integrity of the cell
wall. Lysozymes acts as an anti-microbial agent, causing bacterial
cell wall to burst under its own internal pressure. In addition to
its effectiveness in lysing the bacterial cell wall, lysozyme also
appears to be effective at damaging the cell walls of yeast,
including C. albicans.
will randomly hydrolyze the interior alpha-1, 4-glucosidic bonds of
starch to release simple sugars for digestion. This enzyme works
synergistically with endogenous human amylase to digest starchy
is characterized by its ability to hydrolyze lactose over a wide
range of temperatures and pH. Chantilly’s lactase catalyzes the
hydrolysis of the lactose beta-D-galactoside linkage liberating one
mole of D-glucose and one mole of D-galactose. This enzyme works
synergistically with endogenous human lactase to digest the sugars
found in milk and dairy products.
recommended dosage of Celluzyme is 2 capsules 2 times daily between
Raised to the Power of enzymes
peptide sequences resulting from the partial digestion of gluten
proteins have been linked to the exacerbation of gastrointestinal
conditions caused by autism spectrum disorders and irritable bowel
diseases. One of the enzyme activities required to break down these
peptides has been identified as dipeptidyl peptidase IV (DPP IV). The
lack of this enzyme activity in the small intestine due to the above
conditions prevents the digestion of these peptide fragments. These
peptide fragments, if left undigested, are thought to elicit immune
responses that can inflame the lining of the small intestine. Also,
in the case of autism spectrum disorders it has been postulated that
these peptides have systemic effects that can cause certain symptoms
DPP IV is a proprietary formulation of proteases providing a
standardized DPP IV activity. The DPP IV activity in Biocore® DPP IV
is standardized at 5000 units/g (Table 1). Biocore® DPP IV also
provides 300,000 HUT/g and 85 aminopeptidase units per gram of the
product. The recommended dose for Biocore® DPP IV is 100 mg. The
proteases in Biocore® DPP IV are stable in the acidic environment of
the stomach as shown in Figure 1.Inflammatory bowel disease (IBD) is
a collection of chronic disorders that include Crohn’s disease,
ulcerative colitis and celiac disease. A pro-inflammatory cytokine,
tumor necrosis factor (TNF-), plays an important role in many forms
of IBD. Many successful drugs for IBD like Infliximab have
anti-TNFactivity. This category of drugs is expensive however; and
the cost of treating a single patient per year can range from $25,000
to $30,000. These therapies also have to be administered
intravenously, necessitating a visit to a medical facility each time.
The mechanism of action of anti-TNF- therapies involve the binding to
or cleaving of TNF-, resulting in the inactivation of the
inflammatory action of TNF-. Our research has shown that the
proteases in Biocore® DPP IV can selectively cleave and inactivate
TNF- in vitro. We have also used an animal model of acute TNF-
induced intestinal inflammation to show that the proteases in
Biocore® DPP IV have significant therapeutic promise as anti TNF-
of the statements above have been evaluated by the FDA. This product
is not intended to diagnose, treat, cure or prevent disease.
u n d I n f o r m a t i o n